These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2995172)

  • 1. Conditions for proper formaldehyde inactivation of foot and mouse disease alhydrogel vaccines.
    Barteling SJ
    Dev Biol Stand; 1985; 60():323-9. PubMed ID: 2995172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formaldehyde inactivation of foot-and-mouth disease virus. Conditions for the preparation of safe vaccine.
    Barteling SJ; Woortmeyer R
    Arch Virol; 1984; 80(2-3):103-17. PubMed ID: 6326708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging settled opinions in classic foot-and-mouth disease vaccine preparation.
    Barteling SJ; Anemaet DA
    Dev Biol Stand; 1987; 66():531-8. PubMed ID: 3034709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification, characterisation and safety testing of foot-and-mouth disease virus antigens eluted from alhydrogel vaccines.
    Visser N; Woortmeyer R
    Dev Biol Stand; 1981; 50():277-83. PubMed ID: 6176487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde.
    Barteling SJ; Cassim NI
    Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sheep-pox vaccine prepared from formaldehyde inactivated virus adsorbed to aluminium hydroxide gel.
    Sólyom F; Perenlei L; Roith J
    Acta Microbiol Acad Sci Hung; 1982; 29(2):69-75. PubMed ID: 6291337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines.
    Brown F
    Dev Biol Stand; 1991; 75():37-41. PubMed ID: 1665462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innocuity testing of foot-and-mouth disease vaccines. I. Formaldehyde-inactivated alhydrogel vaccines.
    Barteling SJ; Woortmeyer R; Visser N
    J Biol Stand; 1983 Oct; 11(4):297-304. PubMed ID: 6315736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods of testing of safety of the anti-foot-and-mouth disease vaccine].
    Dannacher G; Fédida M; Coudert M; Perrin M
    Dev Biol Stand; 1976; 35():271-8. PubMed ID: 198294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative testing of the quality of foot-and-mouth disease vaccines prepared with different virus inactivators].
    Dilovski M; Tekerlekov P
    Vet Med Nauki; 1983; 20(5-6):41-5. PubMed ID: 6318423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined method (suspension-monolayer) of preparing an inactivated foot-and-mouth disease vaccine].
    Genov I; Tivchev G; Veleva E; Tekerlekov P; Shopov I
    Vet Med Nauki; 1981; 18(5):57-63. PubMed ID: 6275604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Binary ethyleneimine as an inactivator of the foot-and-mouth disease virus].
    Tekerlekov P; Veleva E
    Vet Med Nauki; 1985; 22(3):3-8. PubMed ID: 2986348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic quality of foot-and-mouth disease virus.
    Strobbe R
    Dev Biol Stand; 1976; 35():311-21. PubMed ID: 198301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological studies with cell cultured aluminium hydroxide gel adsorbed formalin inactivated foot and mouth disease type Asia I monovalent vaccine.
    Negi BS; Kumar S
    Indian Vet J; 1970 Jul; 47(7):555-61. PubMed ID: 4318813
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
    Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
    Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
    Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
    Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial replacement of serum with peptone and lactalbumin hydrolysate for the production of foot-and-mouth disease vaccine in BHK-21 cells.
    Saha SN; Sen AK
    Acta Virol; 1989 Aug; 33(4):338-43. PubMed ID: 2574940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine.
    Aarthi D; Ananda Rao K; Robinson R; Srinivasan VA
    Biologicals; 2004 Sep; 32(3):153-6. PubMed ID: 15536046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Developments in foot-and-mouth disease (FMD) vaccine production (author's transl)].
    Barteling SJ
    Tijdschr Diergeneeskd; 1980 Sep; 105(17):695-8. PubMed ID: 6252656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innocuity testing of foot-and-mouth disease vaccines. II. Aziridine-inactivated antigen produced in baby hamster kidney cells.
    Barteling SJ
    J Biol Stand; 1983 Oct; 11(4):305-12. PubMed ID: 6315737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.